ICNEA 2761—Biopharmaceutical manufacturing

Where 2761 sits

1. C Manufacturing industry
2. 27 Pharmaceutical manufacturing industry
3. 276 Biopharmaceutical product manufacturing
4. 2761 Biopharmaceutical manufacturing

What 2761 includes

• Refers to the production activities of using biotechnology to produce biochemical drugs.
• Includes the following biopharmaceutical manufacturing activities：
• Enzyme biochemical preparations: trypsin preparations, chymotrypsin preparations, bromelain preparations, streptokinase preparations, recombinant streptokinase preparations, double-chain enzyme preparations, urokinase preparations, lysozyme preparations, coenzyme Q10 preparations, coenzyme I preparations, compound coenzyme preparations, aspartameEnzyme preparations, pancreatic enzyme preparations, multi-enzyme preparations, pepsin preparations, sugary pepsin preparations, amylase preparations;
• Amino acid and protein drugs: acetylcysteine preparations, catharostine preparations, mestan hydrochloride preparations, cystine preparations, lysine hydrochloride preparations, glutamic acid preparations, aspartic acid preparations, aspartate amide preparations, compound amino acid preparations, compound amino acid preparations, amino acid drugs for injection and infusion, Other amino acids and protein drugs;
• Fatty drug preparations: fatty drugs for injection, fatty drug capsules, fatty tablets, and other fatty drug preparations;
• Nucleic acid pharmaceutical preparations: sodium adenosine triphosphate preparations, adenosine cyclophosphate preparations, inosine preparations, ribonucleic acid preparations, other nucleic acid pharmaceutical preparations;
• Toxoids: adsorption and refining of diphtheria toxoids, adsorption and refining of diphtheria tetanus two toxins, adsorption and refining of tetanus toxoids, adsorption and refining of tetanus*gas gangrene quadruple toxins, staphylococcal toxins, other toxins;
• Antiserum: antivenom serum, anti-rabies serum, anti-anthrax serum, anti-dysentery serum, refined anti-adenovirus serum, anti-lymphocyte serum, other antiserum;
• Blood products: globulin, albumin, blood product preparations;
• Cytokines: interferon preparations, thymosin preparations, transfer factor preparations, hepatocellular ghrelin preparations, interleukin preparations;
• Diagnostic biological products: mycin, bacterial fluid, bacteria, blood cells for diagnosis, antigen for diagnosis, hemagglutinin for diagnosis, serum for diagnosis, toxins for testing, biological kits for diagnosis;
• Biological agents: biological bacteria and tablets, biological kits, microbial media, and other biological agents;
• Medical reagents for patients: blood type reagents, chemical preparations for image examination, organ function examination agents;
• Diagnostic tests and experimental reagents for non-patients (part): diagnostic or experimental reagents with backing, diagnostic or experimental reagents without backing;
• Other biochemical drugs;
• Antibody drugs for the treatment of malignant tumors;
• Antibody drugs for autoimmune diseases;
• Antibody drugs for nervous system diseases;
• Antibody drugs for other refractory diseases;
• Genetically engineering protein drugs (genetically engineering protein drugs with low immunogenicity, good stability, strong targeting, long-lasting and high bioavailability);
• Cell therapy products for malignant tumors;
• Gene therapy drugs for malignant tumors;
• Cell therapy products for other refractory diseases;
• Gene therapy drugs for other refractory diseases;
• Specific immunoglobulins and other products;
• Peptide drugs;
• Bispecific antibody;
• Antibody-coupled drugs;
• Adoptive immune cell therapy;
• Stem cell transplantation treatment;
• Oncolytic virus.

What 2761 excludes

• Genetic engineering drug manufacturing, included in 2762 (Genetic engineering drug and vaccine manufacturing);
• Vaccine manufacturing, included in 2762 (Genetic engineering drugs and vaccine manufacturing).

2761 in other systems